Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis
Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis
复制标题
DOI：
10.3748/wjg.v12.i26.4191
复制
发表时间：
2006-07-14
影响因子：
4.3
通讯作者：
Vernic, Corina
中科院分区：
文献类型：
--
作者：
Sporea, Ioan;Popescu, Alina;Vernic, Corina
目的：目的：评价聚乙二醇干扰素α 2a对慢性丙型肝炎患者长期血液透析的反应。所有患者转氨酶升高超过6个月，抗HCV抗体阳性，PCR HCV-RNA阳性。我们用PEG-干扰素α 2a 180 μ g/wk治疗48 wk。治疗12周后，我们评估了生化和早期病毒学应答（EVR）。在治疗结束时，我们评估了生化应答，在治疗结束后24周，我们评估了持续病毒学应答（SVR）。结果：2例患者在治疗的前12 wk脱落，2例在治疗的前12 wk后脱落。治疗12 wk后，8例患者中7例生化应答和EVR，1例生化应答但持续病毒血症。我们不得不减少聚乙二醇干扰素的剂量为135 μ g/周的2例。6例患者中3例（50%）在治疗结束后24 wk出现SVR。意向治疗分析显示，10例患者中有3例（30%）发生了SVR。副作用发生在大多数患者（流感样综合征，血小板减少症或白细胞减少症），但他们并没有迫使停止treatment.CONCLUSION：聚乙二醇干扰素α 2a（40 ku）治疗12周后，在慢性血液透析慢性丙型肝炎患者，EVR获得87.5%（7/8）的情况下。在完成48 wk治疗的50%的病例（3/6例患者）中实现了SVR。(c)2006年，WJG出版社。All rights reserved.
AIM: To evaluate the response to pegylated-interferon alpha 2a in chronic hepatitis C patients on chronic haemodialysis.METHODS: Ten patients with chronic C hepatitis were enrolled in this study. All had increased aminotransferases for more than 6 mo, positive antiHCV antibodies and positive PCR HCV-RNA. We administrated Peg-Interferon alpha 2a 180 mu g/wk for 48 wk. After 12 wk of treatment we evaluated the biochemical and early virological response (EVR). At the end of the treatment we evaluated the biochemical response and 24 wk after the end of the treatment we evaluated the sustained virological response (SVR). We monitored the side-effects during the treatment.RESULTS: Two patients dropped out in the first 12 wk of treatment and 2 after the first 12 wk of treatment. After 12 wk of treatment, 7 out of 8 patients had biochemical response and EVR and 1 had biochemical response but persistent viremia. We had to reduce the dose of pegylated-interferon to 135 mu g/wk in 2 cases. Three out of 6 (50%) patients had SVR 24 wk after the end of the treatment. Intention-to-treat analysis showed that 3 out of 10 patients (30%) had SVR. Side-effects occurred in most of the patients (flu-like syndrome, thrombocytopenia or leucopoenia), but they did not impose the discontinuation of treatment.CONCLUSION: After 12 wk of treatment with Peg-Interferon alpha 2a (40 ku) in patients on chronic haemodialysis with chronic C hepatitis, EVR was obtained in 87.5% (7/8) of the cases. SVR was achieved in 50% of the cases (3/6 patients) that finished the 48 wk of treatment. (c) 2006 The WJG Press. All rights reserved.